文献速递外周动脉疾病

荷兰LimFlow注册研究中经皮深静脉动脉化的一年结局

One-year outcomes of percutaneous deep vein arterialization in the Dutch LimFlow registry.
PubMed 文献 · J Vasc Surg · 2026-09-29

该前瞻性多中心注册研究纳入23例无标准血运重建选择的慢性肢体威胁性缺血(NO-CLTI)患者共26条肢体,行LimFlow系统经皮深静脉动脉化(pDVA)。12个月无截肢生存率69.2%、保肢率80.8%、总生存率88.5%,疼痛与生活质量改善,但一期通畅率仅6.6%。

要点

  • pDVA在NO-CLTI患者中12个月无截肢生存率69.2%、保肢率80.8%。
  • 12个月一期通畅率6.6%,85%肢体需再干预维持通畅。
  • 疼痛评分显著下降(P<.001),VascuQoL-25生活质量均值从37%升至68%。

核心结论

  • pDVA在NO-CLTI患者中12个月安全有效,多数患者避免了大截肢和死亡。
  • pDVA后生活质量似有改善,但需更大规模研究确认。

研究设计与样本

  • 荷兰前瞻性多中心注册研究,2020年5月至2024年6月纳入23例NO-CLTI患者共26条肢体。
  • 患者平均年龄64±12岁,20例男性,全部Rutherford 5类,17例(77.3%)WIfI 4期。

主要发现

  • 技术成功率100%,12个月无截肢生存率69.2%、保肢率80.8%、总生存率88.5%。
  • 12个月一期通畅率6.6%、一期辅助通畅率27.3%、二期通畅率35.7%。
  • 85%肢体行再干预维持通畅,58%再干预促进pDVA成熟。
  • 中位伤口愈合时间6.9个月,12个月时73.4%愈合。
  • 12个月内疼痛评分显著下降(P<.001),VascuQoL-25均值从37%升至68%(基于有限数据)。

临床怎么用

  • 对于无标准血运重建选择的CLTI患者,pDVA可作为减少大截肢风险的血管内替代方案。
  • pDVA术后需密切监测并积极再干预以维持通畅和促进通路成熟。

局限性

  • 样本量小(23例患者26条肢体),结果需更大规模研究确认。
  • 生活质量分析基于有限可用数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Percutaneous deep vein arterialization (pDVA) offers a potential endovascular alternative for reducing the risk of major amputation in patients with chronic limb-threatening ischemia (CLTI) who have no standard revascularization options "no-option" CLTI (NO-CLTI). METHODS: In this prospective, multicenter registry conducted in the Netherlands between May 2020 and June 2024, patients with NO-CLTI underwent pDVA using the LimFlow system (Inari Medical). The primary end point was amputation-free survival at 12 months. Secondary outcomes included limb salvage, overall survival, patency, pain scores, wound healing, transcutaneous oxygen pressure, and quality of life (QoL). RESULTS: A total of 26 limbs of 23 patients with NO-CLTI (mean age, 64 ± 12 years; 20 men) were included, all classified as Rutherford category 5 and 17 (77.3%) as Wound Ischemia and foot Infection stage 4. Thirteen (53.8%) patients suffered from diabetes mellitus and six (21.7%) from renal insufficiency. Technical success was 100%. Amputation-free survival was 69.2%, limb salvage 80.8%, and overall survival 88.5% at 12 months. Primary patency, primary-assisted patency, and secondary patency rates at 12 months were 6.6%, 27.3%, and 35.7%, respectively. Reinterventions were performed to maintain patency in 85% of the limbs and 58% for maturation of the pDVA. Median time to wound healing was 6.9 months, with 73.4% healed at 12 months. Pain scores decreased significantly (P <.001) in 12 months. QoL improved from a mean of 37% to 68% on the VascuQoL-25, though these analyses were based on limited available data. CONCLUSIONS: pDVA in patients with NO-CLTI is safe and effective at 12 months, preventing major amputation and mortality in the majority of patients. QoL also appeared to improve following pDVA. These observations warrant confirmation in larger studies. CLINICAL RELEVANCE: This study strengthens existing evidence on the effectivity and safety of percutaneous deep vein arterialization using the LimFlow system (Inari Medical) in patients with "no-option" chronic limb-threatening ischemia. Our data demonstrated a 100% technical success rate and comparable amputation-free survival and limb salvage to other percutaneous deep vein arterialization studies. Notably, this prospective and well-phenotyped cohort uniquely incorporated patient-reported outcome measures, showing improvements in pain, transcutaneous oxygen pressure and quality of life.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Stolk DJ, Nugteren MJ, van den Heuvel D, et al. One-year outcomes of percutaneous deep vein arterialization in the Dutch LimFlow registry. J Vasc Surg. 2026. PMID: 42810697. doi:10.1016/j.jvs.2026.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。